- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Bioactive Molecules
- Anti-infection
- Apoptosis
- Autophagy
- Cell Cycle/DNA Damage
- Cytoskeleton
- Epigenetics
- GPCR/G Protein
- Immunology/Inflammation
- JAK/STAT Signaling
- MAPK/ERK Pathway
- Membrane Transporter/Ion Channel
- Metabolic Enzyme/Protease
- Neuronal Signaling
- NF-κB
- PI3K/Akt/mTOR
- PROTAC
- Protein Tyrosine Kinase/RTK
- Stem Cell/Wnt
- TGF-beta/Smad
- Vitamin D Related/Nuclear Receptor
- Others
- Methylation
- Cytoskeletal Signaling
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. 57415-44-8] Flecainide hydrochloride
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-W010950A |
| Brand: | MCE |
| CAS: | 57415-44-8 |
Overview
| MDL | MFCD19982476 |
|---|---|
| Molecular Weight | 450.80 |
| Molecular Formula | C17H21ClF6N2O3 |
| SMILES | O=C(NCC1NCCCC1)C2=CC(OCC(F)(F)F)=CC=C2OCC(F)(F)F.[H]Cl |
Summary
Flecainide hydrochloride is a potent and orally active antiarrhythmic agent. Flecainide hydrochloride blocks the cardiac fast inward Na + current (INa) and the rapid component of the delayed rectifier K + current. Flecainide hydrochloride prolongs the action potential duration (APD) in ventricular and atrial muscle fibres. Flecainide hydrochloride has the potential for the research of fetal tachycardias [1] [2] [3] .
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT05213104 | Assistance Publique - Hôpitaux de Paris|Fonds de Dotation ACTION |
Patent Foramen Ovale|Atrial Fibrillation|Cryptogenic Stroke
|
March 23, 2022 | Phase 3 |
| NCT01833455 | University of Wisconsin, Madison |
Ventricular Premature Complexes|Blood Pressure
|
February 2013 | Phase 2 |
| NCT03685149 | Wojciech Zareba|University of Rochester |
Arrhythmogenic Right Ventricular Cardiomyopathy
|
July 31, 2019 | Phase 2 |
| NCT02624765 | Edgar Jaeggi|Canadian Institutes of Health Research (CIHR)|St George´s, University of London|The Hospital for Sick Children |
Fetal Atrial Flutter Without Hydrops|Fetal Supraventricular Tachycardia Without Hydrops|Fetal Supraventricular Tachycardia With Hydrops
|
February 2016 | Phase 3 |
| NCT00189319 | MEDA Pharma GmbH & Co. KG|Viatris Inc. |
Atrial Fibrillation
|
September 2003 | Phase 4 |
| NCT04837261 | Tampere University Hospital|Helsinki University Central Hospital|Kuopio University Hospital|Oulu University Hospital|Turku University Hospital |
Supraventricular Tachycardia
|
April 15, 2021 | |
| NCT00392106 | ProRhythm, Inc. |
Atrial Fibrillation
|
April 2006 | Phase 3 |
| NCT02110537 | Kyunghee University Medical Center|Ministry of Health & Welfare, Korea |
Persistent Atrial Fibrillation
|
March 2014 | Not Applicable |
| NCT04991896 | AHEPA University Hospital|Skylitseio General Hospital |
Atrial Fibrillation|Arrhythmias, Cardiac
|
January 1, 2020 | |
| NCT00000504 | National Heart, Lung, and Blood Institute (NHLBI) |
Arrhythmia|Cardiovascular Diseases|Heart Diseases|Ventricular Arrhythmia
|
September 1982 | Phase 2 |
| NCT02248753 | Maastricht University Medical Center|ZonMw: The Netherlands Organisation for Health Research and Development |
Atrial Fibrillation
|
October 2014 | Not Applicable |
| NCT00000526 | National Heart, Lung, and Blood Institute (NHLBI) |
Cardiovascular Diseases|Coronary Disease|Death, Sudden, Cardiac|Heart Arrest|Heart Diseases|Myocardial Infarction|Myocardial Ischemia|Ventricular Arrhythmia
|
August 1986 | Phase 3 |
| NCT03539302 | InCarda Therapeutics, Inc. |
Paroxysmal Atrial Fibrillation (PAF)
|
May 29, 2018 | Phase 2 |
| NCT00002996 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) |
Pain
|
February 1998 | Phase 2 |
| NCT02294955 | Uppsala University Hospital|Swedish Heart Lung Foundation |
Atrial Fibrillation|Quality of Life
|
May 2008 | Not Applicable |
| NCT03587558 | Keimyung University Dongsan Medical Center|Chong Kun Dang Pharmaceutical Corp. |
Ventricular Premature Complexes|Outflow Tract|Carvedilol
|
September 5, 2017 | Phase 4 |
| NCT01646281 | Maastricht University Medical Center |
Atrial Fibrillation
|
August 2012 | Phase 4 |
| NCT01117454 | Vanderbilt University Medical Center |
Catecholaminergic Polymorphic Ventricular Tachycardia
|
December 2011 | Not Applicable |
| NCT00702117 | Hospital Clinic of Barcelona |
Atrial Fibrillation|Tachycardia, Ventricular|Brugada Syndrome
|
June 2008 | Phase 4 |
| NCT00215774 | Atrial Fibrillation Network|German Federal Ministry of Education and Research|Meda Pharmaceuticals|German Research Foundation |
Atrial Fibrillation
|
March 2005 | Not Applicable |
| NCT02302274 | NYU Langone Health |
Brugada Syndrome|Arrhythmogenic Right Ventricular Cardiomyopathy
|
July 1, 2010 | |
| NCT03162120 | Elpen Pharmaceutical Co. Inc. |
Atrial Fibrillation|Recurrence
|
September 1, 2018 | Phase 2|Phase 3 |
| NCT00523978 | Medtronic Cardiac Rhythm and Heart Failure|Medtronic |
Paroxysmal Atrial Fibrillation
|
October 2006 | Phase 3 |
| NCT05549752 | Hippocration General Hospital|Win Medica|Pharmassist Ltd |
Atrial Fibrillation Paroxysmal|Coronary Artery Disease Without Residual Ischemia
|
October 1, 2022 | Phase 3 |
| NCT00000556 | National Heart, Lung, and Blood Institute (NHLBI) |
Arrhythmia|Atrial Fibrillation|Cardiovascular Diseases|Heart Diseases
|
March 1995 | Phase 3 |
| NCT00408473 | MEDA Pharma GmbH & Co. KG|3M|Viatris Inc. |
Atrial Fibrillation
|
Phase 4 | |
| NCT03845010 | Maatschap Cardiologie Zwolle |
Ventricular Premature Beats
|
February 12, 2019 | Not Applicable |
| NCT02347111 | University of Illinois at Chicago|Medtronic |
Atrial Fibrillation
|
December 31, 2020 | Phase 4 |
| NCT03005366 | David Filgueiras-Rama|Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III|Hospital San Carlos, Madrid |
Paroxysmal Atrial Fibrillation
|
January 2017 | Phase 4 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
References
- [1] Echt DS, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991 Mar 21;324(12):781-8.
- [2] Aliot E, et al. Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation. Europace. 2011 Feb;13(2):161-73.
- [3] Allan LD, et al. Flecainide in the treatment of fetal tachycardias. Br Heart J. 1991 Jan;65(1):46-8.
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.